STAFF BOARD
Article
CHAIRMAN
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 2, March-April 2018
ORIGINAL
AN INDIRECT COMPARISON OF EFFICACY AND SAFETY OF CEFTOLOZANE/TAZOBACTAM, CEFTAZIDIME/AVIBACTAM VERSUS MERO PENEM IN COMPLICATED INTRA-ABDOMINAL INFECTIONS
FERRIOLS LISART RAFAEL, PÉREZ PITARCH ALEJANDRO, FERRIOLS LISART FRANCISCO, ALÓS ALMIÑANA MANUEL


Objective. The aim of this study was to perform an indirect comparison to assess the comparative efficacy and safety of ceftolozane/tazobactam plus metronidazole, ceftazidime/avibactam plus metronidazole and meropenem in monotherapy in hospitalized adult patients diagnosed of complicated intra-abdominal infection.

Method. Databases consulted were MEDLINE, Institute of Science Information Web of Science, EMBASE, Índice Médico Español and . Two independent reviewers extracted relevant data and assessed risk of bias. Pairwise treatment effects were estimated using a random effects meta-analysis and reported as odds ratios (OR) with 95% confidence interval (95% CI).

Results. Five publications were included. Three studies compared ceftazidime/ avibactam plus metronidazole vs. meropenem, and the other two, ceftolozane/tazobactam plus metronidazole vs. meropenem. The trials showed a high methodological quality. Ceftazidime/avibactam was statistically inferior to meropenem in the microbiologically intention to treat population (OR = 0.72; 95% CI: 0.53-0.97) but achieved no clinical relevance. All other pairwise comparisons showed no differences in the efficacy or safety. Indirect comparison between ceftazidime/avibactam and ceftolozane/tazobactam showed no difference in efficacy (OR = 1.05; 95% CI:
0.64-1.69) or safety (OR =1.29; 95% CI: 0.77-2.32). No heterogeneity was found in the whole network. Publication bias was not statistically significant.

Conclusion. Efficacy and safety of the treatment of complicated intra-abdominal infections in adult patients with ceftazidime/avibactam or ceftolozane/tazobactam plus metronidazole is not better than meropenem in monotherapy. The choice between ceftazidime/avibactam or ceftolozane/tazobactam should be made according
to other criteria than efficacy or safety.

AVIBACTAM – CEFTAZIDIME DRUG COMBINATION – CEFTOLOZANE DRUG – COMBINATION – INTRA-ABDOMINAL INFECTIONS – INDIRECT COMPARISON – MEROPENEM – TAZOBACTAM



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25